Amanda Gee, Lymphoma Web Pioneer
Back in 1994, it was the wild west of the Internet. No Google, few pages of really good content, and a fair amount of what was online for medical information was in a non-web format called Gopher. It was in these days that Hodgkin's Lymphoma survivor Amanda Gee, in England, started a website devoted to Hodgkin's. It was possibly the first, certainly it was the largest at the time with about 20 or so pages.
Amanda had plans to form a Hodgkin's charity and she registered www.cansurvive.org.uk and started to move her site to CanSurvive. Alas, the site went offline not long after that (it now has had a "Building" stub page for years). Efforts to find out how Amanda is have turned up empty. I liken her to Amelia Earhart, pioneering and then being lost in the sunset. Maybe someone will let us know how she's getting along.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
